ASP Isotopes (NASDAQ:ASPI) Trading 10.1% Higher – Time to Buy?

Shares of ASP Isotopes Inc. (NASDAQ:ASPI) traded up 10.1% during trading on Thursday . The stock traded as high as $7.32 and last traded at $7.3420. 1,633,294 shares traded hands during trading, a decline of 68% from the average session volume of 5,049,644 shares. The stock had previously closed at $6.67.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $11.00 price target on shares of ASP Isotopes in a research note on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research note on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $13.00.

ASP Isotopes Stock Performance

The stock has a market cap of $969.96 million, a PE ratio of -3.70 and a beta of 3.26. The company has a fifty day moving average price of $5.12 and a 200 day moving average price of $5.90. The company has a quick ratio of 4.37, a current ratio of 4.39 and a debt-to-equity ratio of 0.69.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings data on Wednesday, May 20th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.06. The firm had revenue of $8.36 million for the quarter, compared to the consensus estimate of $3.68 million. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.

Insider Buying and Selling

In related news, COO Robert Ainscow sold 22,500 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $5.21, for a total value of $117,225.00. Following the sale, the chief operating officer directly owned 1,490,317 shares of the company’s stock, valued at $7,764,551.57. This trade represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Duncan Moore sold 11,642 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $5.21, for a total value of $60,654.82. Following the completion of the sale, the director directly owned 1,044,928 shares in the company, valued at $5,444,074.88. The trade was a 1.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 90,704 shares of company stock valued at $463,252 over the last ninety days. 14.40% of the stock is owned by insiders.

Institutional Trading of ASP Isotopes

Several large investors have recently added to or reduced their stakes in the stock. Encompass Capital Advisors LLC bought a new stake in ASP Isotopes in the first quarter valued at $30,551,000. Alyeska Investment Group L.P. boosted its holdings in ASP Isotopes by 73.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock valued at $26,191,000 after acquiring an additional 2,072,851 shares in the last quarter. Vanguard Group Inc. boosted its holdings in ASP Isotopes by 37.9% in the third quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock valued at $43,451,000 after acquiring an additional 1,241,024 shares in the last quarter. Rovida Investment Management Ltd boosted its holdings in ASP Isotopes by 28.1% in the fourth quarter. Rovida Investment Management Ltd now owns 4,100,000 shares of the company’s stock valued at $21,894,000 after acquiring an additional 900,000 shares in the last quarter. Finally, UBS Group AG boosted its holdings in ASP Isotopes by 150.3% in the fourth quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock valued at $12,875,000 after acquiring an additional 1,445,165 shares in the last quarter. Institutional investors own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.